Trombólise no Acidente Vascular Cerebral Isquêmico
uma mudança conceitual
DOI:
https://doi.org/10.34024/rnc.2005.v13.8835Palavras-chave:
Acidente cerebrovascular, Terapia trombolítica, Transtornos cerebrovascularesResumo
A trombólise foi a primeira estratégia eficaz no tratamento do acidente vascular cerebral (AVC) isquêmico agudo. Desde sua aprovação em 1996 nos Estados Unidos e em 2001 no Brasil, sua utilização tem crescido exponencialmente. Apesar de sua eficácia, poucos pacientes são candidatos ao tratamento, mas novas técnicas de terapia intra-arterial, triagem por neuroimagem e de potencialização da trombólise por ultra-som prometem aumentar ainda mais a proporção de pacientes beneficiados. Nesse artigo, revisamos os principais conceitos no tratamento do AVC agudo que se modificaram com o advento da trombólise
Referências
Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 1964;189:373. DOI: https://doi.org/10.1001/jama.1964.03070050039011
Fletcher AP, Alkjaersig N, Lewis M et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976;7:135-142. DOI: https://doi.org/10.1161/01.STR.7.2.135
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735-2740. DOI: https://doi.org/10.1161/hs1201.100209
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581. DOI: https://doi.org/10.1056/NEJM199512143332401
Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363:768. DOI: https://doi.org/10.1016/S0140-6736(04)15692-4
Szoeke CE, Parsons MW, Butcher KS et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003;178:324-328. DOI: https://doi.org/10.5694/j.1326-5377.2003.tb05223.x
Albers GW, Bates VE, Clark WM et al. Intravenous tissuetype plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283:1145. DOI: https://doi.org/10.1001/jama.283.9.1145
Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283:1151. DOI: https://doi.org/10.1001/jama.283.9.1151
Marler JR, Tilley BC, Lu M et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55:1649. DOI: https://doi.org/10.1212/WNL.55.11.1649
Sociedade Brasileira de Doencas Cerebrovasculares (SBDCV). Consenso brasileiro de trombólise no acidente vascular cerebral isquêmico. Arq Neuropsiquiatr 2002; 60:675-680. DOI: https://doi.org/10.1590/S0004-282X2002000400032
Sorensen AG, Copen WA, Ostergaard L et al. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time. Radiol 1999;210:519-527. DOI: https://doi.org/10.1148/radiology.210.2.r99fe06519
Hacke W, Albers G, Al-Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66. DOI: https://doi.org/10.1161/01.STR.0000149938.08731.2c
Silverman IE, Beland DK, Bohannon RW, Ohki SK, Spiegel GR. Expanding the range of therapies for acute ischemic stroke: the early experience of the Regional Stroke Center at Hartford Hospital. Conn Med 2004; 68:419-429.
Kothari R, Jauch E, Broderick E et al. Acute stroke: Delays to presentation and emergency department evaluation. Ann Emerg Med 1999; 33:3. DOI: https://doi.org/10.1016/S0196-0644(99)70431-2
O’Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: Why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999; 33:9. DOI: https://doi.org/10.1016/S0196-0644(99)70411-7
Grotta JC, Burgin WS, El-Mitwalli A et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001;58:2009-2013. DOI: https://doi.org/10.1001/archneur.58.12.2009
Brandt T, von Kummer R, Muller-Kuppers M, Hacke W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996; 27:875. DOI: https://doi.org/10.1161/01.STR.27.5.875
Arnold M, Nedeltchev K, Schroth G et al. Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosur Psychiatr 2004; 75:857. DOI: https://doi.org/10.1136/jnnp.2003.020479
Furlan A, Higashida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282:2003. DOI: https://doi.org/10.1001/jama.282.21.2003
Lewandowski CA, Frankel M, Tomsick TA et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial Stroke 1999; 30:2598. DOI: https://doi.org/10.1161/01.STR.30.12.2598
Ernst R, Pancioli A, Tomsick T et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 2000; 31:2552. DOI: https://doi.org/10.1161/01.STR.31.11.2552
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35:904. DOI: https://doi.org/10.1161/01.STR.0000121641.77121.98
Junghans U, Seitz RJ, Wittsack HJ et al. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases. Radiology 2001; 221:795. DOI: https://doi.org/10.1148/radiol.2213010444
Seitz RJ, Hamzavi M, Junghans U et al. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke 2003; 34:1932. DOI: https://doi.org/10.1161/01.STR.0000080535.61188.A6
Straub S, Junghans U, Jovanovic V et al. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 2004; 35:705. DOI: https://doi.org/10.1161/01.STR.0000117094.41638.EE
Seitz RJ, Meisel S, Moll M et al. The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions. Neurol 2004; 62:2110. DOI: https://doi.org/10.1212/01.WNL.0000129480.17345.4A
Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36:880-890. DOI: https://doi.org/10.1161/01.STR.0000157668.39374.56
Alexandrov, AV Molina CA, Grotta JC et al. Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351:2170. DOI: https://doi.org/10.1056/NEJMoa041175
Advisory Working Group on Stroke Center Identification Options of the American Stroke Association. Recommendations for improving the quality of care through stroke centers and systems: an examination of stroke center identification options. Stroke 2002;33:e1-7. DOI: https://doi.org/10.1161/hs0102.101262
Friedrich MAG, Martins SO, Almeida AG et al. Safety and efficacy of IV thrombolysis in ischemic stroke: The experience from Porto Alegre, Brazil. Stroke 2005 (Resumo da World Stroke Conference).
DATASUS, 1998.
